BioVex Raises $30 Million
BioVex Inc., a Woburn, Mass.-based drug company whose lead candidate is designed to help treat advanced melanoma, has raised $30 million in new Series F funding. This brings the round total to $70 million, including a $40 million first close back in March. Morningside Venture, Ventech and MVM Life Science Partners co-led the new tranche, and were joined by fellow new backers Sectoral Asset Management and Ysios Capital Partners. Forbion Capital Partners had led the initial tranche, alongside Credit Agricole Private Equity, Harris & Harris Group, Innoven Partners, New Science Ventures, Triathlon Medical Venture Partners and Scottish Equity Partners. BioVex has now raised around $180 million.
10 November 2009•5 mins read
